Diffuse large B-cell lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Patient-Derived Models to Identify Effective Therapies in Aggressive Large B-Cell Lymphomas

  Massachusetts General Hospital· Boston, United States· US$600,075 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Enhancing CAR-T cell therapy for DLBCL

  Washington University· Saint Louis, United States· US$548,528 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Viral and Cellular microRNA Dependencies in HIV-associated Lymphomas

  Northwestern University· Chicago, United States· US$644,961 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · R37

  The role of MGA in the pathogenesis of Richter Transformation

  Weill Medical Coll of Cornell Univ· New York, United States· US$425,741 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · R01

  INHIBITION OF EZH2 TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER

  University of Pennsylvania· Philadelphia, United States· US$704,044 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spain· EU contribution €226,441· until Jun 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment (CAR-TIME)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Germany· EU contribution €1,499,875· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

9 of 114 running projects, newest first. Listed amounts together: US$67.2m + €2.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Source

• REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

  NCT07887750· Regeneron Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 31
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 29
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

• Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma.

  J Med Chem, Nov 2026

• CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.

  Cancer Lett, Sept 2026

• Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma.

  Cells, Sept 2026

• Optimization of a Series of Novel 1H-Pyrrolo[3,2-c]pyridine-Based USP1 Inhibitors with Potent In Vivo Antitumor Activity.

  J Med Chem, Sept 2026

• Discovery of CDK8/19 inhibitors as lead compounds for IL-6-dependent lymphoma enabled by the formal synthesis of cortistatin A.

  Sci Adv, Sept 2026

• A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

  Blood Cancer Discov, Sept 2026

• Hedgehog/GLI1 regulates EMT and cancer stem cell properties via the GLI1-Bmi1 axis in diffuse large B-cell lymphoma.

  Sci Rep, Jul 2026

• BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability.

  J Hematol Oncol, Jun 2026

• A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas.

  Sci Rep, Jun 2026

• Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation.

  Ann Hematol, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.